Phreesia, Inc. (NYSE:PHR) Director Sells $318,343.52 in Stock

Phreesia, Inc. (NYSE:PHR) Director Michael Weintraub sold 15,152 shares of Phreesia stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $21.01, for a total transaction of $318,343.52. Following the sale, the director now directly owns 242,827 shares of the company’s stock, valued at $5,101,795.27. This represents a 5.87 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Phreesia Trading Up 1.3 %

Shares of NYSE PHR opened at $21.18 on Thursday. The business’s 50 day moving average is $20.32 and its 200-day moving average is $21.79. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.03. Phreesia, Inc. has a 1-year low of $14.55 and a 1-year high of $29.16.

Phreesia (NYSE:PHR) last posted its quarterly earnings data on Wednesday, September 4th. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.06. Phreesia had a negative return on equity of 39.34% and a negative net margin of 25.73%. The firm had revenue of $102.12 million for the quarter, compared to analysts’ expectations of $101.76 million. Analysts expect that Phreesia, Inc. will post -1.23 EPS for the current fiscal year.

Hedge Funds Weigh In On Phreesia

Several institutional investors and hedge funds have recently modified their holdings of PHR. Franklin Resources Inc. raised its stake in Phreesia by 3.0% in the 3rd quarter. Franklin Resources Inc. now owns 1,497,631 shares of the company’s stock worth $31,495,000 after purchasing an additional 42,973 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Phreesia by 4.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,245,797 shares of the company’s stock worth $28,397,000 after acquiring an additional 55,934 shares during the period. M&T Bank Corp increased its position in Phreesia by 4.6% during the 3rd quarter. M&T Bank Corp now owns 35,127 shares of the company’s stock worth $801,000 after purchasing an additional 1,535 shares in the last quarter. Barclays PLC boosted its holdings in shares of Phreesia by 83.6% during the 3rd quarter. Barclays PLC now owns 94,929 shares of the company’s stock valued at $2,163,000 after acquiring an additional 43,225 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in Phreesia during the 3rd quarter worth $247,000. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Canaccord Genuity Group reiterated a “buy” rating and set a $34.00 price objective on shares of Phreesia in a report on Thursday, September 5th. JPMorgan Chase & Co. increased their price objective on Phreesia from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Monday, September 9th. JMP Securities reissued a “market outperform” rating and issued a $30.00 target price on shares of Phreesia in a research report on Thursday, September 5th. DA Davidson reissued a “buy” rating and issued a $32.00 price objective on shares of Phreesia in a research report on Thursday, September 5th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $29.00 target price on shares of Phreesia in a report on Thursday, September 5th. One equities research analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $29.42.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.